
Salah-Eddin Al-Batran: I extend my warmest congratulations to my friends and colleagues Claus Rödel and Emmanouil Fokas as well as all members, investigators and study nurses of the German Rectal Cancer Study Group, for successfully completing their 18.1 trial.
Quoting Salah-Eddin Al-Batran, Director at The Frankfurt Institute of Clinical Cancer Research, on LinkedIn:
“Friends and colleagues,
I extend my warmest congratulations to my friends and colleagues Claus Rödel and Emmanouil Fokas, as well as all members, investigators and study nurses of the German Rectal Cancer Study Group, for successfully completing their 18.1 trial. This large trial involved the randomization of 702 patients with rectal cancer, comparing short-course Radiotherapy versus Chemoradiotherapy, followed by Consolidation Chemotherapy, and Selective Organ Preservation for MRI-defined Intermediate and High-risk Rectal Cancer Patients.
The remarkable recruitment achieved in this study serves as an exemplary demonstration of how investigator-initiated research can efficiently enroll patients from complex multidisciplinary trials, emphasizing the significance of academic research groups like those at the University Cancer Center Frankfurt. We take pride in the involvement of our Frankfurt Institute of Clinical Cancer Research in conducting this study.
The ACO/ARO/AIO-18.1 study introduces several novel and innovative elements aimed at optimizing multimodal rectal cancer treatment, building on the foundation laid by the preceding CAO/ARO/AIO-04 and CAO/ARO/AIO-12 randomized trials. These innovations include:
1. Patient selection based on strict, quality-controlled MRI features of intermediate and high-risk characteristics, complementing our ACO/ARO/AIO-18.2 trial for “low-risk” rectal cancer.
2. Chemoradiotherapy regimens incorporating 5-Fluorouracil/oxaliplatin at doses and intensities proven to be effective and well-tolerated without compromising treatment compliance, as seen in CAO/ARO/AIO-04.
3. A treatment sequence involving Cathode Ray Tube, Computed Tomography, and surgery/Watch and Wait adopting the TNT approach established by CAO/ARO/AIO-12 and OPRA trial.
4. Surgical stratification allowing for Watch and Wait management for carefully selected patients showing clinical complete response (cCR).
Hence, the study hypothesizes that Total Neoadjuvant Therapy with 5-Fluorouracil/oxaliplatin-CRT followed by consolidation chemotherapy may increase organ preservation while maintaining Disease-Free Survival (DFS) compared to the RAPIDO-like short-course Radiotherapy followed by consolidation chemotherapy. Looking forward to seeing the results!”
Source: Salah-Eddin Al-Batran/LinkedIn
-
15:11 04/12/23 | BlogTom Powles: This is the next chapter IMO
-
08:33 04/12/23 | BlogRoberto Iacovelli: There is HOPE for kidney cancer patients!
-
16:39 03/12Rami Manochakian: A special supplement highlighting major data from the IASLC 2023
-
16:28 03/12Jamie Ostroff: A call to action to improve the widespread adoption of smoking cessation guidelines in cancer care
-
16:18 03/12Karen Merritt: The tragic story of Dr. Anil Kapoor who died after one dose of 5FU, just like my mother
-
16:14 03/12Mark Storey: From asymptomatic to oligo, we remain a critical component of treatment
-
15:51 03/12Ishwaria Subbiah: Interesting new study published in the JCO CCI evaluates the utility and privacy of synthetic breast cancer clinical trial data sets
-
16:34 03/12Tedros Adhanom Ghebreyesus: Grateful to Namibia’s Prime Minister Saara Kuugongelwa-Amadhila for her commitment to health
-
18:08 02/12100 Influential Celebrities in Oncology: The 2023 Edition – Part 5
-
16:50 02/12Mara Antonoff: When your famous friends come back to visit their humble beginnings
-
16:12 02/12Nirmala Bhoo Pathy: To all the working mothers out there
-
07:43 02/12Nagashree Seetharamu: What’s in your he(ART)?
-
16:26 04/12SIOP 2023 by Numbers! - International Society of Paediatric Oncology
-
16:43 02/12In our recent survey, nearly 1,700 ASCO members shared feedback on the ABIM MOC requirements - ASCO
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
17:33 02/12Leukaemia and Myeloma Research UK awarded grants to Neil Rodrigues and Concetta Bubici
-
19:18 01/12Maria Kavallaris has been awarded the prestigious Royal Society of NSW Walter Burfitt Prize for 2023 - Children's Cancer Institute
-
18:35 01/12Sara Beltrán Ponce: Honored to be awarded the Eleanor Montague Distinguished Resident Award in Radiation Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College